Amanda Y. Tam, MS, FNP-BC The standard of care with curative intent for resectable or borderline resectable pancreatic adenocarcinoma involves surgery and then adjuvant chemotherapy. High-risk features include the following:…
Taylor A. Aldridge, MMS, PA-C Pancreatic ductal adenocarcinoma (PDAC) is a notoriously aggressive gastrointestinal malignancy with an overall 5-year survival rate of 5%.1 This grim prognosis is primarily due to…
The Oncology Connection Fam-trastuzumab-deruxtecan-nxki (Enhertu, Daiichi-Sankyo/AstraZeneca), or T-DXd, led to a high intracranial response rate in patients with active brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast…
Beth Sandy, MSN, CRNP Proton pump inhibitors (PPIs) are very common to use in a wide variety of patients to treat many different symptoms of anything from a more serious…
Megan B. May, PharmD, BCOP, and Tori A. Gray, PharmD Candidate 2022 Non-small cell lung cancer (NSCLC) is the third most common type of cancer in the Unites States (US).…
Beth Sandy, MSN, CRNP As a nurse practitioner working in thoracic medical oncology, I have seen the changes in non-small cell lung cancer (NSCLC) change dramatically over the past 20…
Introduction Cluster of differentiation 40 (CD40) is a costimulatory molecule that is expressed by B cells, antigen-presenting cells, non-immune cells, and tumors, which makes this molecule an emerging immunotherapy target…
Christina Bartholomew | Dec 13, 2021 10:46:21 AM Although treatment strategies for patients with metastatic gastric cancer who have failed prior lines of therapy remain limited, novel agents such as trastuzumab…
Christian Watts Pharm.D., MSHI Candidate, Larry Buie Pharm.D., BCOP, FCCP, FASHP, Beth Sandy, MSN, CRNP | Dec 13, 2021 12:27:20 PM Introduction: Epidermal growth factor receptor (EGFR) in non-small cell lung cancer…
Grashma Vadakkel, PharmD | Feb 10, 2021 8:18:59 AM Bladder cancer is the sixth most common cancer in the United States. Patients with locally advanced or metastatic disease have poor long-term…